Abbott Laboratories Surges to 116th in Trading Volume with $13.65 Billion Day

On April 4, 2025, Abbott Laboratories (ABT) experienced a significant trading volume of $13.65 billion, marking a 65.51% increase from the previous day. This surge placed ABT at the 116th position in terms of trading volume for the day. However, the stock price of ABT declined by 5.46%, marking the second consecutive day of decline, with a total decrease of 5.68% over the past two days.

Abbott Laboratories, a global healthcare company, is set to release its fiscal Q1 2025 earnings results before the market opens on April 16. Analysts anticipate the company to report a profit of $1.07 per share, reflecting a 9.2% increase from the same period last year. The company has a history of meeting or exceeding earnings estimates in the past four quarters. For fiscal 2025, analysts project an EPS of $5.15, a 10.3% increase from the previous year, with further growth anticipated for fiscal 2026.

In the fourth quarter of 2024, Abbott reported adjusted EPS of $1.34, meeting expectations and showing a 12.6% year-over-year growth. Despite a slight revenue miss, the company's strong organic sales growth, particularly in the Medical Devices segment, reassured investors. The segment saw a 14% organic growth, driven by notable gains in Diabetes Care and Structural Heart. Abbott's upbeat 2025 guidance, projecting adjusted EPS of $5.05 - $5.25 and organic sales growth of 7.5% - 8.5%, further bolstered investor sentiment.

Piper Sandler recently maintained an Overweight rating and a $133.00 price target for Abbott Laboratories, reflecting continued confidence in the company's performance. The analysts' consensus view on ABT stock is bullish, with a "Strong Buy" rating overall. Among the 25 analysts covering the stock, 17 recommend a "Strong Buy," two suggest a "Moderate Buy," and six indicate a "Hold."